WATCHMAN FLX Pro 유럽 레지스트리
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
-
Aarhus, 덴마크, 8200
- Aarhus University Hospital
-
Copenhagen, 덴마크, 2100
- Rigshospitalet Copenhagen
-
-
-
-
-
Bad Oeynhausen, 독일, 32545
- Herz-und Diabeteszentrum Nordrhein-Westfalen
-
Berlin, 독일, 12203
- Charite, Campus Benjamin Franklin
-
Erfurt, 독일, 99097
- Kath Krankenhaus St Johann Nepomuk
-
Hamburg, 독일, 22763
- Asklepios Klinik Altona
-
Hamburg, 독일, 20099
- Asklepios Klinik Saint Georg
-
Hamburg, 독일, 22417
- Asklepios Klinik Nord Heidberg
-
Lübeck, 독일, 23582
- Universitaetsklinikum Schleswig-Holstein
-
-
-
-
-
Basel, 스위스, 4031
- University Hospital Basel
-
Bern, 스위스, CH-3010
- INSELSPITAL - Universitätsspital Bern
-
-
-
-
-
León, 스페인, 24071
- Hospital de Leon
-
Pamplona, 스페인, 31008
- Clinica Universidad de Navarra
-
Pontevedra, 스페인, 36001
- Complejo Hospitalario Universitario de Pontevedra
-
Pontevedra, 스페인, 36001
- Complejo Hospitalario de Pontevedra
-
Salamanca, 스페인, 37007
- Hospital Clinico Salamanca
-
-
-
-
-
Catania, 이탈리아, 95123
- Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco
-
Milan, 이탈리아, 20138
- Centro Cardiologico Monzino
-
Verona, 이탈리아, 37126
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Poznan, 폴란드, 61-848
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Hospital
설명
Inclusion Criteria:
- Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device.
- Subject has non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) and is clinically indicated for a WATCHMAN FLX™ Pro LAAC device, per the Instructions for Use (IFU).
- Subject or legal representative who are willing and capable of providing informed consent.
- Subject is able and willing to return for required follow-up visits and examinations.
- Subject whose age is 18 years or above, or who is of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subject has a documented life expectancy of less than 12 months.
- Subject who is currently enrolled in another investigational study or registry except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments.
- Intracardiac thrombus is present.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a Closure Device.
- Subject has a known hypersensitivity or contraindications according to IFU.
- Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
WATCHMAN FLX Pro
This arm is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. Approximately 300 patients undergo the LAAC procedure in conjunction with the use of the VersaCross Connect™ LAAC Access Solution. |
The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with a safety event treated with the WATCHMAN FLX Pro
기간: Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. Percutaneous catheter drainage of pericardial effusions, snaring of an embolized device, thrombin injection to treat femoral pseudoaneurysm and minor nonsurgical treatments of access site complications are excluded from this endpoint. |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a safety event treated with the VersaCross Connect™ LAAC Access Solution
기간: Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
Proportion of subjects with one or more of the following events between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later: For all enrolled subjects, who had an attempt to insert the VersaCross Connect™ LAAC Access Solution device, the composite rate of all-cause death, all stroke, systemic embolism, pericardial effusion resulting in interventions*, and ISTH major bleeding. *Pericardial effusion/tamponade requiring pericardiocentesis or surgery to treat |
Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
|
|
Number of participants with a successful VersaCross Connect™ LAAC Access Solution treatment
기간: Completion of transseptal puncture
|
VersaCross Connect™ LAAC Access Solution acute procedural success: Acute Procedural Success is defined as transseptal puncture success (VersaCross RF-wire crossing into left atrium). |
Completion of transseptal puncture
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Arian Sultan, Prof. MD, Asklepios Klinik Saint Georg
- 수석 연구원: Marek Grygier, Prof. MD, PHD, Uniwersytecki Szpital Kliniczny w Poznaniu
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- S2603
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .